Dimeric FAPI with Potential for Tumor Theranostics

Overview

Journal Am J Nucl Med Mol Imaging

Date 2022 Jan 10

PMID 35003891

Authors

Chunxia Qin

Yangmeihui Song

Weibo Cai

Xiaoli Lan

Affiliations

Soon will be listed here.

Abstract

Radionuclide-labeled fibroblast activation protein inhibitors (FAPIs) are popular nuclear imaging probes in recent years. It's of great significance for tumor diagnosis and has great potential in tumor treatment. However, optimization of the probes is needed to further increase tumor uptake and prolong tumor retention for improved treatment efficacy and fewer side effects. In this issue of AJNMMI, Moon et al. reported two squaramide coupled FAPI conjugates (DOTA.(SA.FAPi) and DOTAGA.(SA.FAPi)) and labeled them with Ga. The resulted tracers showed increased tumor accumulation and persistent retention, which led to an advance in PET imaging. The use of dimeric structures provides a feasible strategy to develop radiotherapeutic analogs of FAP inhibitors.

Citing Articles

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Hisada K, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Saito A, Watabe T Int J Mol Sci. 2024; 25(22).

PMID: 39596363 PMC: 11594969. DOI: 10.3390/ijms252212296.

Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls.

Al-Ibraheem A World J Nucl Med. 2024; 23(2):71-72.

PMID: 38933068 PMC: 11199033. DOI: 10.1055/s-0044-1787886.

Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by Ga-FAPI PET/MR scan.

Zhu M, Sun S, Huang L, Chen M, Cai J, Wang Z Am J Nucl Med Mol Imaging. 2024; 14(1):72-77.

PMID: 38500744 PMC: 10944375.

Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?.

Chakravarty R, Song W, Chakraborty S, Cai W Eur J Nucl Med Mol Imaging. 2023; 50(10):2935-2939.

PMID: 37452872 PMC: 10428190. DOI: 10.1007/s00259-023-06338-6.

Q.Clear reconstruction for reducing the scanning time for Ga-DOTA-FAPI-04 PET/MR imaging.

Ruan W, Qin C, Liu F, Pi R, Gai Y, Liu Q Eur J Nucl Med Mol Imaging. 2023; 50(7):1851-1860.

PMID: 36847826 DOI: 10.1007/s00259-023-06134-2.

References

Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K . Fibroblast activation protein targeted therapy using [Lu]FAPI-46 compared with [Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2021; 49(3):871-880. PMC: 8803706. DOI: 10.1007/s00259-021-05554-2. View

Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z . Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J Nucl Med. 2021; 63(6):952-958. PMC: 9157728. DOI: 10.2967/jnumed.121.262533. View

Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T . Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an F-Labeled FAP Inhibitor. J Nucl Med. 2020; 61(12):1806-1813. DOI: 10.2967/jnumed.120.242958. View

Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C . Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of Ga-Labeled FAPI Dimer. J Nucl Med. 2021; 63(6):862-868. PMC: 9157726. DOI: 10.2967/jnumed.121.263016. View

Ma H, Li F, Shen G, Cai H, Liu W, Lan T . Synthesis and Preliminary Evaluation of I-Labeled FAPI Tracers for Cancer Theranostics. Mol Pharm. 2021; 18(11):4179-4187. DOI: 10.1021/acs.molpharmaceut.1c00566. View

Sharma P, Singh S, Gayana S . Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool. Clin Nucl Med. 2020; 46(3):e141-e150. DOI: 10.1097/RLU.0000000000003489. View

Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R . Radiation Dosimetry and Biodistribution of Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med. 2019; 61(8):1171-1177. PMC: 7413240. DOI: 10.2967/jnumed.119.236786. View

Hathi D, Jones E . Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiol Imaging Cancer. 2021; 1(1):e194003. PMC: 7983761. DOI: 10.1148/rycan.2019194003. View

Ballal S, Yadav M, Kramer V, Moon E, Roesch F, Tripathi M . A theranostic approach of [Ga]Ga-DOTA.SA.FAPi PET/CT-guided [Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020; 48(3):942-944. DOI: 10.1007/s00259-020-04990-w. View

10.

Lindner T, Altmann A, Kramer S, Kleist C, Loktev A, Kratochwil C . Design and Development of Tc-Labeled FAPI Tracers for SPECT Imaging and Re Therapy. J Nucl Med. 2020; 61(10):1507-1513. PMC: 7539653. DOI: 10.2967/jnumed.119.239731. View

11.

Kuyumcu S, Kovan B, Sanli Y, Buyukkaya F, Simsek D, Ozkan Z . Safety of Fibroblast Activation Protein-Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04. Clin Nucl Med. 2021; 46(8):641-646. DOI: 10.1097/RLU.0000000000003667. View

12.

Altmann A, Haberkorn U, Siveke J . The Latest Developments in Imaging of Fibroblast Activation Protein. J Nucl Med. 2020; 62(2):160-167. DOI: 10.2967/jnumed.120.244806. View

13.

Yeong C, Cheng M, Ng K . Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B. 2014; 15(10):845-63. PMC: 4201313. DOI: 10.1631/jzus.B1400131. View

14.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J . Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018; 59(9):1415-1422. DOI: 10.2967/jnumed.118.210443. View

15.

Koustoulidou S, Hoorens M, Dalm S, Mahajan S, Debets R, Seimbille Y . Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy. Cancers (Basel). 2021; 13(5). PMC: 7961537. DOI: 10.3390/cancers13051100. View

16.

Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K . Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: Cu- and Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. J Nucl Med. 2019; 61(4):563-569. PMC: 7198371. DOI: 10.2967/jnumed.119.233122. View

17.

Baum R, Schuchardt C, Singh A, Chantadisai M, Robiller F, Zhang J . Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using Lu-FAP-2286: First-in-Humans Results. J Nucl Med. 2021; 63(3):415-423. PMC: 8978187. DOI: 10.2967/jnumed.120.259192. View

18.

Moon E, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S . Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA chelators. EJNMMI Radiopharm Chem. 2020; 5(1):19. PMC: 7391456. DOI: 10.1186/s41181-020-00102-z. View

19.

Moon E, Van Rymenant Y, Battan S, De Loose J, Bracke A, Van der Veken P . In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA.SA.FAPi and DOTA.SA.FAPi. Molecules. 2021; 26(12). PMC: 8226449. DOI: 10.3390/molecules26123482. View

20.

Giesel F, Adeberg S, Syed M, Lindner T, Jimenez-Franco L, Mavriopoulou E . FAPI-74 PET/CT Using Either F-AlF or Cold-Kit Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2020; 62(2):201-207. PMC: 8679591. DOI: 10.2967/jnumed.120.245084. View